LLLucian Lozonschi

Lucian Lozonschi

*This is an algorithmically generated author record based on publicly available information.

Lucian Lozonschi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Georg Lutter

    Department of Cardiovascular Surgery, Christian-Albrechts-University of Kiel, School of Medicine, Kiel, Germany

    2 shared publications
  • Anja Metzner

    Department of Cardiovascular Surgery, Christian-Albrechts-University of Kiel, Kiel, Germany

    1 shared publication
  • Carter T. Smith

    University of Wisconsin School of Medicine Hospitals

    1 shared publication
  • Entela B. Lushaj

    Division of Cardiothoracic Surgery, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53792-3236, USA

    1 shared publication
  • Jan Schoettler

    Klinik für Herz- und Gefäßchirurgie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland

    1 shared publication
  • Jian Hu

    Division of Cardiothoracic Surgery, School of Medicine and Public Health , University of Wisconsin , Madison , USA

    1 shared publication

Latest Publications

  • Cardiac Transplantation

    by Lucian Lozonschi, Carter T. Smith, Niloo M. Edwards

  • Open Access

    Intravital microscopy to study myocardial engraftment

    by Entela B. Lushaj, Jian Hu, Robert Haworth, Lucian Lozonschi

    Tissue engineering and stem cell transplantation are promising novel therapies for myocardial repair. A major barrier to cell survival after transplantation involves inadequate vascularization. Continuous observation of cardiac tissue engraftment and angiogenesis could help understand these processes and allow for identification of the optimal conditions for these therapeutic interventions. We investigated the ability of a skin-fold chamber model to allow for engraftment of differentiated myocardial tissue in mice. Neonatal atrial and ventricular tissues were implanted in the in vivo chambers. All myocardial implants had a high rate of engraftment (86–95%). Tissue engraftment was preceded by a ‘bleeding phase’ in both the atrial and ventricular implants. This occurred earlier in ventricular compared with atrial implants. Spontaneous contractions were observed after an average of 13 days after implantation in all chambers but occurred earlier in ventricular compared with atrial implants. The host cells surrounded the myocardial implants circumferentially, but have limited infiltration into these grafts. This is the first report of successful ectopic engraftment of differentiated myocardium using a skin-fold chamber. This model is invaluable for real-time observation of early angiogenesis and tissue growth during in vivo myocardial engineering and myocardial regeneration.


  • Transcatheter mitral valve stent implantation

    by Lucian Lozonschi, Georg Lutter

    The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)


  • Mitral valved stent implantation: An overview

    by Tim Attmann, Saskia Pokorny, Lucian Lozonschi, Anja Metzner, Martin Marcynski-Bühlow, Jan Schoettler, Jochen Cremer, Georg Lutter

    To date, transcatheter valve implantation is limited to the replacement of pulmonary and aortic valves. The aim of this study was to analyze a valved stent for minimally invasive implantation in the mitral position. A self-expanding mitral valved stent was designed for transapical implantation. Thirty pigs underwent off-pump mitral valved stent implantation with follow-up times of 60 minutes (n = 17) and seven days (n = 13). Transesophageal echocardiography and computed tomography were used to evaluate stent function and positioning. After valved stent deployment, accurate adjustment of the intra-annular position reduced paravalvular leakage in all animals. Accurate positioning was established in all but five animals. The average mean transvalvular gradient across the mitral valve and the left ventricular outflow tract recorded immediately after deployment, six hours and one week were 1.85 ± 0.95 mmHg, 3.45 ± 1.65 mmHg, 4.15 ± 2.3 mmHg and 1.35 ± 1.35 mmHg, 1.45 ± 0.7 mmHg, 1.9 ± 0.65 mmHg, respectively. No valved stent migration, embolization, systolic anterior movement or left ventricular outflow tract obstruction was observed. The mitral valved stent can be deployed in a reproducible manner to achieve reliable stent stability, minimal gradients across the left ventricular outflow tract and adequate stent function in acute and short term experimental settings.